Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Dalteparin × Other × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Classical hematology 3 Sarcoma 2 Plasma cell 1 Other 1 Gynecologic 1 CNS 1

Conditions

Venous Thromboembolism 1 Obesity 1 Neoplasms 1

Interventions

Radiotherapy 5 Surveys and Questionnaires 4 Cisplatin 4 angiotensin I (1-7) 3 alvimopan 3 Radiation 3 Injections 3 Water 2 Vitamin D 2 Tirzepatide 2 RRx-001 2 Mouthwashes 2 Interleukin 1 Receptor Antagonist Protein 2 Drug Therapy 2 Dexmedetomidine 2 Dexamethasone 2 Calcium Dobesilate 2 Amifostine 2 Acetylcysteine 2 tempol 1 peppermint oil 1 pegfilgrastim 1 naloxegol 1 methylnaltrexone 1 linaclotide 1 licogliflozin 1 kang-lai-te 1 isatuximab 1 indole-3-carbinol 1 hydrated silica gel-based toothpaste 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297359 2024-01-23

WAVe

Ottawa Hospital Research Institute

Phase 2 Terminated

Classical hematologyOther

Neoplasms, Obesity, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡